JPRN-UMIN000028081
Completed
未知
A non-interventional, cross-sectional study to investigate the burden of disease in patients with uncontrolled severe asthma in Japan by internet survey - SHIRAHAE study
ConditionsBronchial asthma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Bronchial asthma
- Sponsor
- AstraZeneca K.K.
- Enrollment
- 4000
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who meet the following criterion will be excluded from enrollment in the study: Patients who are unlikely to be able to follow the instructions for the study based on their completion status of questionnaires
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
CAPTURE-IOType 2 Diabetes MellitusJPRN-jRCT1080224506ovo Nordisk Pharma Ltd.8,000
Not yet recruiting
Not Applicable
A non-interventional, cross-sectional study for evaluating factors relating to daily step counts and physical activity in Japanese patients with COPDJPRN-UMIN000033888AstraZeneca.KK500
Not yet recruiting
Not Applicable
A non-interventional, cross-sectional study for evaluating factors relating to daily step counts and physical activity in Japanese patients with COPDCOPDJPRN-UMIN000032962AstraZeneca.KK.500
Not yet recruiting
Not Applicable
A non-interventional, prospective study to evaluate change in physical activity, relationship satisfaction and psychological well-being in patients with rheumatoid arthritis after introduction of the JAK inhibitor filgotinib and also in their partners.M06.8Other specified rheumatoid arthritisDRKS00032128Helios Fachklinik Vogelsang-Gommern, Rheumatologie40
Active, not recruiting
Not Applicable
A study investigating the effectiveness, safety and quality of life in participants with age related visual impairment (macular degeneration) who have switched to faricimab, under real world conditions in Germanyeovascular age related macular degeneration (nAMD)Eye DiseasesISRCTN27514808Roche Pharma (Roche Germany)620